Literature DB >> 31412384

[Pseudoexfoliation Syndrome and Glaucoma].

Matthias Nobl, Marc Mackert.   

Abstract

Pseudoexfoliation (PEX) syndrome is a common, worldwide occurring and age-related disorder characterised by the deposition of extracellular fibrillar material. It is a systemic disease with significant ocular manifestations, including cataract and glaucoma. All structures of the anterior segment are affected leading to multiple specific findings in slit lamp examination. The most prominent findings are white, dandruff like deposits on the anterior surface of the lens or the pupillary border of the iris. Furthermore, PEX syndrome is the most common identifiable cause of open angle glaucoma. PEX glaucoma generally takes a more rapidly progressive course than primary open angle glaucoma. Patients therefore typically need earlier surgical intervention. PEX syndrome is often accompanied by nuclear cataract formation. Cataract extraction tends to be complicated and remains a challenge. Several technique modifications and new devices help to reduce the complication rate. The purpose of this paper is to summarize information regarding ocular manifestations of PEX-syndrome to facilitate an early diagnosis and to present a general view of the treatment of PEX glaucoma. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 31412384     DOI: 10.1055/a-0972-4548

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  One-year outcomes of microshunt implantation in pseudoexfoliation glaucoma.

Authors:  Matthias Nobl; Sigrid Freissinger; Stefan Kassumeh; Siegfried Priglinger; Marc J Mackert
Journal:  PLoS One       Date:  2021-08-27       Impact factor: 3.240

2.  Impact of Pseudoexfoliative Syndrome on Effective Lens Position, Anterior Chamber Depth Changes, and Visual Outcome After Cataract Surgery.

Authors:  Michael Müller; Katarzyna Pawlowicz; Myriam Böhm; Eva Hemkeppler; Christoph Lwowski; Lisa Hinzelmann; Mehdi Shajari; Thomas Kohnen
Journal:  Clin Ophthalmol       Date:  2021-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.